Monday
Mar162015

Ablative Solutions receives innovation award

March 13, 2015 - Cardiovascular News

Ablative Solutions was the recipient of a “Top Cardiovascular Innovation Award” from Cardiovascular Research Technologies for the Peregrine system. The Peregrine system is a percutaneous catheter designed to deliver diagnostic and therapeutic agents through vessel walls to the outer region of arteries. more

Ablative Solutions was the recipient of a “Top Cardiovascular Innovation Award” from Cardiovascular Research Technologies for the Peregrine system. The Peregrine system is a percutaneous catheter designed to deliver diagnostic and therapeutic agents through vessel walls to the outer region of arteries. - See more at: http://www.cxvascular.com/cn-latest-news/cardiovascular-news---latest-news/ablative-solutions-receives-innovation-award#sthash.cNaaNrCZ.dpuf
Ablative Solutions was the recipient of a “Top Cardiovascular Innovation Award” from Cardiovascular Research Technologies for the Peregrine system. The Peregrine system is a percutaneous catheter designed to deliver diagnostic and therapeutic agents through vessel walls to the outer region of arteries. - See more at: http://www.cxvascular.com/cn-latest-news/cardiovascular-news---latest-news/ablative-solutions-receives-innovation-award#sthash.cNaaNrCZ.dpuf
Friday, 13 Mar 2015 14:32
Friday, 13 Mar 2015 14:32
Monday
Feb162015

Ablative Solutions welcomes hypertension leader to its Scientific Advisory Board

February 12, 2015 - Cardiovascular News

Michael Weber has been appointed to Ablative Solutions’ Scientific Advisory Board. Weber is an expert in the areas of hypertension and preventive cardiology, and is currently a professor of medicine at SUNY Downstate College of Medicine in, New York City, USA. He is also the editor-in-chief of The Journal of Clinical Hypertension. Weber was one of the founders of The American Society of Hypertension and has previously served as its president.  more

Michael Weber has been appointed to Ablative Solutions’ Scientific Advisory Board. Weber is an expert in the areas of hypertension and preventive cardiology, and is currently a professor of medicine at SUNY Downstate College of Medicine in, New York City, USA. He is also the editor-in-chief of The Journal of Clinical Hypertension. Weber was one of the founders of The American Society of Hypertension and has previously served as its president. - See more at: http://www.cxvascular.com/cn-latest-news/cardiovascular-news---latest-news/ablative-solutions-welcomes-hypertension-leader-to-its-scientific-advisory-board-#sthash.Jbv48RW3.dpuf
Wednesday
Jan142015

Tissue Regeneration Systems Adds Business Development Executive

January 14, 1024 - PR Newswire

MAF-1 portfolio company Tissue Regeneration Systems welcomes Sharon Schulzki as Senior Vice President of Business Development. Prior to joining TRS, Schulzki served as Vice President of Surgical Affairs for Depuy Synthes Spine, a division of Johnson & Johnson Corporation. She was the Chief Operating Officer of NSpine, a start-up medical device company acquired by Synthes in 2007. Prior to that, Schulzki served as Chief Operating Officer of MacroPore Biosurgery, and Vice President of Marketing for the Howmedica division of Pfizer Corporation. "Sharon has an impressive track record of building successful companies in the orthopedics, spine, and biomaterials spaces and we are delighted to have her join our senior management team," said Jim Fitzsimmons, president and chief executive officer. "She brings an essential skill set to TRS as we execute our business plan of forging corporate partnerships around our novel technology platform." more

Wednesday
Nov122014

Bio-pesticide startup raises $4 million

November 6, 2014 - Grand Rapids Business Journal

MAF-1 portfolio company Vestaron has concluded its Series C financing round by raising $4 million. The company said last week that the funding brings its Series C total to $14 million, after the startup raised $10 million in the round this summer. The oversubscribed Series C financing round had a number of investors, including Anterra Capital, Cultivian Sandbox Ventures, Southwest Michigan First Life Science Venture Fund, Open Prairie Ventures, Pangaea Ventures and Michigan Accelerator Fund I. Vestaron focuses on the production of naturally occurring and “environmentally safe” insecticides for farmers and has invested in developing a product using a peptide found in spider toxins. more

Thursday
Oct232014

Metabolic Solutions Development Company Appoints Robert L. Zerbe, MD to Board of Managers

October 23, 2014 - PR Newswire 

Metabolic Solutions Development Company, LLC (MSDC) announced today that it has appointed Robert L. Zerbe, MD to its Board of Managers.  Dr. Zerbe co-founded and is chief executive officer of QuatRx Pharmaceuticals Company, a venture-backed drug development company that developed the recently launched product for postmenopausal dyspareunia, Osphena®. Prior to QuatRx, he served as Senior Vice President of Worldwide Clinical Research and Development of Pfizer (formerly Parke-Davis), where he led the clinical development programs for Neurontin® and Lipitor®.

"We are extremely pleased to have recruited a pharmaceutical executive of Bob's caliber to join our Board," said Stephen Benoit, MSDC's chief executive officer. "The breadth and depth of his clinical development experience, which includes the most successful pharmaceutical product ever developed, and leadership of a successful venture-backed drug development company will add significantly to the strategic development of our mid-stage clinical pipeline." more

Monday
Oct132014

Venture Capitalists Return to Backing Science Start-Ups

October 12, 2014 - The New York Times

Michigan Accelerator Fund I portfolio company, Vestaron, was featured in The New York Times article Venture Capitalists Return to Backing Science Start-Ups. “We’re trying to revolutionize pesticides,” said John Sorenson, Vestaron’s chief executive. “Thankfully, venture funders are starting to invest again in real, hard-core science and innovation.”  more

Thursday
Oct092014

The promise of chemical renal denervation

September 5, 2014 - Interventional News

Tim Fischell, CEO and chief medical officer of MAF-1 portfolio company Ablative Solutions, recently contributed an article to cxvascular Zone Interventional News. In the article Fischell points out the sobering results from Symplicity-HTN 3 trial,1 which found that Medtronic’s Symplicity system was not associated with significant reductions in blood pressure compared with a sham procedure, have left some casual observers sceptical about the promise of renal denervation as a means to manage resistant hypertension. However, more sophisticated experts in the field have begun to shed light on the root cause of the trial’s failure. It has become increasingly clear that the major problem with radiofrequency-mediated renal denervation is poor efficacy caused by incomplete and inconsistent sympathetic nerve injury and, consequently, “inadequate denervation”. “Non-responders” are not necessarily unresponsive to renal sympathetic denervation—they are just not adequately denervated. more

Tuesday
Sep302014

MAF-1 Managing Director named dealmaker of the year

September 28, 2014 - MiBiz

John Kerschen, Managing Director of Michigan Accelerator Fund I and Charter Capital Partners, was named a finalist in the MiBiz Deal and Dealmakers of the Year Awards in the Advisor category for the second year in a row. The Grand Rapids-based investment banking firm of late served as an adviser on three acquisitions made by Crystal Flash Energy that doubled its locations from nine to 18 and brought in nearly 6,000 new customers and more than $70 million in annual revenue to the company. Kerschen co-manages the $15.1 million Michigan Accelerator Fund I that invested more than $1 million into three life sciences companies, serves as the fund manager for the new Novus Biotechnology Fund in Kalamazoo that this year closed its first round by raising $2 million, and advised Grand Rapids Aseptic Manufacturing on a $9.8 million investment round that closed in June.

The transition out of the deep economic recession of a few years ago created new opportunity for Charter Capital Partners. What Kerschen calls “an amazing amount of capital” still awaits deployment, either through M&A or investing in the lower middle market that Charter Capital serves. “The excess supply of capital is really a driver in what’s getting done today,” said Kerschen. “The financial buyers and strategic buyers are both in good, strong positions to do transactions.” more
Thursday
Sep042014

MCVA Venture Fellow Linda Chamberlain sees possibility in every deal

September 4, 2014 - Michigan Venture Capital Association

When Linda Chamberlain became a MVCA Venture Fellow at Grand Rapid’s Michigan Accelerator Fund I in 2012, she assumed her previous experiences leading corporate innovation business units, a high tech start-up, a life sciences incubator and a university center for entrepreneurship made her experienced enough to remain objective, even skeptical, of investment opportunities. As she nears the end of her Fellowship period two years later, Chamberlain has found that wasn’t always the case. “The process of venture investing offers the honor of sharing in the big vision of the entrepreneur, as well as the practical roadmap on how they are going to make it happen,” she remarks.  “It affords- at least at that first pitch!- the time to refrain from applying objective filters, applaud the dream, and for me, exercise my inner technology geek and get excited about the commercial possibilities!” more

Sunday
Aug312014

Vestaron raises $10 million in Series C

MAF-1 porfolio company, Vestaron Corp., a developer of biopesticides based in spider venom, raised $10 million in Series C preferred stock financing. Chicago-based Cultivian Sandbox Ventures, which specializes in funding food and agricultural companies, led the group of investors that also included the Southwest Michigan First Life Science Venture Fund, Open Prairie Ventures, Michigan Accelerator Fund I, and Pangaea Ventures. The funding will help Vestaron commercialize its first product, which received U.S. Food and Drug Administration approval in February. more